Predictive Markers for the Acquired Immunodeficiency Syndrome (AIDS) in Hemophiliacs: Persistence of p24 Antigen and Low T4 Cell Count
- M. Elaine Eyster, MD;
- James O. Ballard, MD;
- Mitchell H. Gail, MD, PhD;
- James E. Drammond, MS; and
- James J. Goedert, MD
Abstract
Study Objective: To investigate the predictive value of assays for human immunodeficiency virus (HIV) p24 antigen, p24 antibody, and gpl20 antibody compared with T4 cell counts.
Design: Prospective cohort selected from persons who had HIV-antibody seroconversion.
Patients: Eighty-seven persons with hemophilia with an actuarial cumulative acquired immunodeficiency syndrome (AIDS) incidence of 26% (CI, 12% to 40%), 8 years after HIV-antibody seroconversion.
Intervention: None.
Measurements and Main Results: Human immunodeficiency virus p24 antigen was detected in 8 of 74 (11%) of the patients without AIDS and 7 of 13 (54%) of the patients with AIDS. The 2-year actuarial incidence of AIDS was 24% (CI, 0% to 48%) after detection of p24 antigen, 16% (CI, 0% to 34%) after loss of p24 antibody, 20% (CI, 0% to 45%) after loss of gp120 antibody, 31% (CI, 15% to 47%) after a T4 count of less than 200 cells/μL, and 67% (CI, 31% to 100%) after a T4 count of less than 200 cells/μL among those patients positive for p24 antigen. Very low numbers of T4 and T8 lymphocytes, presence of p24 antigen in serum, and absence of p24 antibody all had some predictive value. However, only p24 antigen (relative hazard 6.0, P = 0.008) and T4 counts (relative hazard 5.3, P = 0.002 with T4 count < 200 cells/μL) independently predicted AIDS up to 12 months before diagnosis.
Conclusions: Strong predictors of AIDS are p24 antigenemia or low T4 counts. Detection of p24 antigen is highly specific and complementary to the greater sensitivity of low T4 counts. These findings have important implications regarding prognosis, counseling, and the planning of clinical trials.
Article and Author Information
-
From the Pennsylvania State University School of Medicine, Hershey, Pennsylvania; Biological Products Laboratory, Inc., Frederick, Maryland; and the National Cancer Institute, Bethesda, Maryland. For current author addresses, see end of text.
-
Grant Support: Supported in part by contract ME-87032 from the Pennsylvania Department of Health, contract MCJ-422004-03-0 from the Department of Health and Human Services, a grant from the Brandywine Valley Hemophilia Foundation, and contracts NO1-CP-85649 and NO1-CO-74102 from the National Cancer Institute.
-
Requests for Reprints: M. Elaine Eyster, MD, Milton S. Hershey Medical Center, P.O. Box 850, Hershey, PA 17033.
-
Current Author Addresses: Drs. Eyster and Ballard: Milton S. Hershey Medical Center, P.O. Box 850, Hershey, PA 17033.
Drs. Gail and Goedert: Epidemiology and Biostatistics Program, National Cancer Institute, Bethesda, MD 20892.
Mr. Drummond: Biological Products Laboratory, Program Resources, Inc., Frederick, MD 21701.
- © 1989 American College of Physicians
Most Read